QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Vol. 19, Issue 8, 3192-3202, August 2008

This Article Abstract Full Text (PDF) All Versions of this Article: E08-02-0161v1 19/8/3192    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ruan, W. Articles by Desbarats, J. Search for Related Content PubMed PubMed Citation Articles by Ruan, W. Articles by Desbarats, J.

A Novel Juxtamembrane Domain in Tumor Necrosis Factor Receptor Superfamily Molecules Activates Rac1 and Controls Neurite Growth

Department of Physiology, McGill University, Montréal, Québec H3G 1Y6, Canada

Submitted February 15, 2008; Revised April 29, 2008; Accepted May 19, 2008
Monitoring Editor: Kunxin Luo

	ABSTRACT

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Members of the tumor necrosis factor receptor (TNFR) superfamily control cell fate determination, including cell death and differentiation. Fas (CD95) is the prototypical "death receptor" of the TNFR superfamily and signals apoptosis through well established pathways. In the adult nervous system, Fas induces apoptosis in the context of neuropathology such as stroke or amyotrophic lateral sclerosis. However, during nervous system development, Fas promotes neurite growth and branching. The molecular mechanisms underlying Fas-induced process formation and branching have remained unknown to date. Here, we define the molecular pathway linking Fas to process growth and branching in cell lines and in developing neurons. We describe a new cytoplasmic membrane proximal domain (MPD) that is essential for Fas-induced process growth and that is conserved in members of the TNFR superfamily. We show that the Fas MPD recruits ezrin, a molecule that links transmembrane proteins to the cytoskeleton, and activates the small GTPase Rac1. Deletion of the MPD, but not the death domain, abolished Rac1 activation and process growth. Furthermore, an ezrin-derived inhibitory peptide prevented Fas-induced neurite growth in primary neurons. Our results define a new domain, topologically and functionally distinct from the death domain, which regulates neuritogenesis via recruitment of ezrin and activation of Rac1.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Members of the tumor necrosis factor receptor (TNFR) superfamily are homotrimeric cell surface receptors that mediate pleiotropic biological effects, including death, proliferation, and differentiation. These receptors have no intrinsic enzymatic activity, but they use adaptor proteins to activate a variety of signaling pathways, including the p42/44 and p38 mitogen-activated protein kinases (MAPKs), nuclear factor-B (NF-B), c-Jun NH₂-terminal kinase, and the canonical caspase cascade leading to apoptosis (Aggarwal, 2003). Fas, also known as CD95, is the archetypal death receptor of the TNFR superfamily (Nagata and Golstein, 1995). Its only endogenous ligand is Fas ligand (FasL; CD178). Fas was originally described as a lymphocyte receptor able to transduce apoptotic signals (Trauth et al., 1989; Yonehara et al., 1989). However, Fas signaling can promote proliferation, differentiation, cytokine secretion, and tissue regeneration as well as cell death (Alderson et al., 1993, 1994; Biancone et al., 1997; Barcena et al., 1999; Desbarats et al., 1999; Tsutsui et al., 1999; Desbarats and Newell, 2000; Shinohara et al., 2000; Choi et al., 2002; O'Brien et al., 2002; Peter et al., 2007). Fas is expressed principally in the immune system, where it regulates cell numbers by inducing apoptosis (Brunner et al., 1995; Dhein et al., 1995; Ju et al., 1995). In the adult nervous system, neurons generally express very low or undetectable levels of Fas constitutively, but readily up-regulate Fas in response to injury, such as oxidative stress, trauma, ischemia, pharmacological toxicity, excitotoxicity, and during some neurodegenerative diseases (for review, see Lambert et al., 2003). In the adult nervous system in the context of neuropathology, Fas can induce apoptosis, notably in models of stroke and amyotrophic lateral sclerosis (Martin-Villalba et al., 2001; Raoul et al., 2002). However, during embryonic development and in the early postnatal period, neurons coexpress Fas and FasL (French and Tschopp, 1996; Bechmann et al., 1999; Zuliani et al., 2006). In this context, activation of Fas by FasL does not induce apoptosis, but rather promotes branching in axons and dendrites (Sakic et al., 1998; Zuliani et al., 2006). Interestingly, Fas is expressed constitutively in human adult neural progenitor cells isolated from the subventricular zone and does not induce apoptosis in these neurons (Ricci-Vitiani et al., 2004). Therefore, during development and in neural progenitor cells, Fas regulates neuronal morphology rather than apoptosis.

Molecular mechanisms of Fas-induced apoptosis are well defined (for review, see Peter and Krammer, 2003). The cytoplasmic adaptor protein Fas-associated death domain (FADD) associates with the death domain of Fas, followed by recruitment and activation of caspases-8 and/or -10. Together, Fas, FADD and caspase-8/10 form the death-inducing signaling complex that triggers apoptosis. In contrast, the upstream molecular events regulating Fas-mediated neurite growth are unknown. The p42/44 extracellular signal-regulated kinase (ERK) cascade, an MAPK pathway, has been implicated in Fas-mediated neuritogenesis in sensory neurons (Desbarats et al., 2003), but it is not required for Fas-induced neurite branching in hippocampal neurons (Zuliani et al., 2006). The domain(s) of Fas and the Fas-interacting molecule(s) controlling neurite growth and branching have not previously been identified.

Here, we show that Fas directly regulates morphology, in the absence of apoptosis, in cell lines and in primary cortical neurons from embryonic mice. We demonstrate for the first time that Fas activates the small GTPase Rac1. We define a novel membrane-proximal domain (MPD) of Fas that recruits ezrin; is essential for Fas-induced Rac1 activation and process growth; and is distinct from the death domain. This newly defined MPD is shared with other members of the TNFR superfamily, including the low-affinity p75 nerve growth factor receptor (NGFR) and TNFR2. Our findings elucidate the membrane-proximal molecular mediators of Fas-induced process growth in developing neurons, thereby defining a new nonapoptotic pathway through which members of the TNFR superfamily can regulate process growth and branching.

	MATERIALS AND METHODS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Cell Lines and Transfections
We obtained SH-SY5Y and COS-7 cells from the American Type Culture Collection (Manassas, VA) and maintained them in DMEM supplemented with 10% fetal calf serum (FCS). We performed transient transfections in 80–90% confluent cultures in six-well tissue culture plates containing glass coverslips, by using 4.0 µg of plasmid DNA and 10 µl of Lipofectamine 2000 in 2.5 ml of DMEM/10% FCS. Transfection efficiency was 50–80% as determined by flow cytometry. For process quantification, we plated 6 x 10⁴ cells/well onto poly-D-lysine (PDL)–coated 16-well chamber slides and transfected the cells with 0.2 µg of plasmid and 0.5 µl of Lipofectamine 2000 in Opti-MEM (Invitrogen, Carlsbad, CA). Media were changed after 4–6 h, and experiments were performed beginning 18 h after transfection.

Constructs
We amplified the full-length and death-domain deleted (DD) human Fas sequences by polymerase chain reaction (PCR) amplification of Invitrogen cDNA clone ID 4514272 (accession no. BC012479) encoding human Fas isoform 1 (5' primer, GGAAGCGAATTCACTTCG; 3' primer for full length, GTTTTTCGAATTCGACCAAGCTTTGG; 3' primer for DD, GGTGATATAGAATTCCAAGTC). We cloned the amplified sequences into the EcoR1 site of the pCMV-Tag4A vector (Stratagene, La Jolla, CA), to generate Fas-C'-terminal-FLAG–tagged proteins (Fas-FLAG and DD-Fas-FLAG). We produced the Fas191-204 construct by PCR amplification of pCMV-Fas (5' primer, CAATTCCACTAATTGTTTGGGTGGAAAACCAAGGTTCTCATGAATC; 3' primer, GATTCATGAGAACCTTGGTTTTCCACCCAAACAATTAGTGGAATTG). In all experiments, we used the pCMV-Tag4-luciferase control expression vector encoding luciferase-FLAG (Stratagene) as a transfection control.

Cell Death Assays
We plated 5 x 10³ HEP1-6 or COS-7 cells or 10⁴ Jurkat cells per well, in 96-well plates. HEP1-6 and COS-7 cells were transfected with 0.2 µg of Fas-FLAG or luc-FLAG control plasmids in 0.5 µl of Lipofectamine 2000. Twenty-four hours after transfection, we changed the media and added 50 ng/ml agonistic anti-human Fas antibody CH11 where indicated. Jurkat cells were not transfected and were treated with CH11 at the concentrations indicated. In Figure 8, Jurkat cells were pretreated for 30 min with SERLI or IETD (200 µM) before stimulation with CH11. After an additional 24-h incubation, we determined cell viability by the colorimetric 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate assay (Roche Diagnostics, Indianapolis, IN) according to the manufacturer's instructions. Jurkat cells were used as a positive control for CH11-mediated apoptosis in assays using HEP 1-6 or COS-7 cells, and in some experiments, agonistic anti-mouse Fas antibody (clone Jo2; 5 µg/ml) was included as a positive control for maximal killing through endogenous Fas.

GTPase Activation Assays
We used the Cdc42/Rac1-interactive binding (CRIB) domain of human p21 activated kinase 1 protein 1B (PAK1B) as a specific probe for activated Rac1 and Cdc42 and the Rho binding domain (RBD) of Rho-associated kinase (ROCK) as a specific probe for activated RhoA, in glutathione transferase (GST) pull-down assays (Manser et al., 1994). We cotransfected COS-7 cells with Fas-FLAG or control luciferase (luc)-FLAG, and with myc-tagged Rac1, Cdc42, or RhoA, kindly provided by Dr. N. Lamarche-Vane (McGill University, Montreal, Canada). For detection of endogenous Rac1 activation, we transfected cells only with Fas-FLAG or control luc-FLAG vectors. We lysed the cells in GTPase assay buffer (25 mM HEPES, pH 7.5, 1% NP-40, 10 mM MgCl₂, 100 mM NaCl, 5% glycerol, 1 mM phenylmethylsulfonyl fluoride [PMSF], 5 mM NaF, 5 mM sodium orthovanadate, and 1 µg/ml each aprotinin and leupeptin) 20 h after transfection, and incubated the cleared lysate with glutathione-Sepharose 4B beads (GE Healthcare, Little Chalfont, Buckinghamshire, United Kingdom) coupled to GST-CRIB or GST-RBD for 1 h at 4°C. We washed the beads four times, boiled them in 2x SDS sample buffer, and then subjected the eluted proteins to electrophoresis on 12% polyacrylamide gels. We transferred the proteins to nitrocellulose membranes and blotted them with anti-myc antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) to detect transfected GTPases, or anti-Rac1 (Millipore, Billerica, MA) for endogenous Rac1. We quantified the ratio of activated GTPase (in the pull-down) to total GTPase (in the lysate) by densitometry, and calculated Fas-induced GTPase activity as follows: (activated/total GTPase in Fas-transfected cells)/(activated/total GTPase in luciferase-transfected cells).

Immunoblotting and Coimmunoprecipitation (coIP)
We lysed COS-7 cells grown to 90% confluence in 10-cm plates then transiently transfected with luc-FLAG or Fas-FLAG in 1.5 ml of modified radioimmunoprecipitation assay lysis buffer (50 mM Tris-HCl, pH 7.4; 1% NP-40; 0.25% sodium deoxycholate; 150 mM NaCl; 1 mM EDTA; 1 mM PMSF; 1 µg/ml each aprotinin, leupeptin, pepstatin; 1 mM NaF; and 1 mM sodium orthovanadate). We centrifuged and precleared the lysates, and then we immunoprecipitated precleared lysates with 4 µg/ml antibody (anti-FLAG M2 [Sigma-Aldrich], anti-ezrin clone 3C12 [Sigma-Aldrich], or mouse immunoglobulin G [IgG]1 isotype control [Santa Cruz Biotechnology]) for 2 h followed by a 1-h incubation with protein G beads at 4°C. We washed the beads four times, boiled them in 2x SDS sample buffer, and then subjected the proteins to electrophoresis on 10% polyacrylamide gels. We transferred the proteins to nitrocellulose membranes and blotted them with anti-FLAG polyclonal antibodies (Sigma-Aldrich) or ezrin antibodies (clone 3C12; Sigma-Aldrich), followed by secondary horseradish peroxidase-conjugated antibodies (Bio-Rad, Hercules, CA), and developed the bands with ECL kit reagents (GE Healthcare).

GST-Fusion Proteins and Binding Assays
We designed a series of GST-Fas constructs composed of the transmembrane and cytoplasmic regions of Fas, either full length or with the deletions described above (DD and 191-204). We excised appropriate Fas fragments from the respective Fas-pCMV-Tag4A constructs using BamHI (restriction site 10 amino acids extracellular to the transmembrane domain) and EcoR1, ligated the fragments into pGEX4T-1 (Clonetech, Mountain View, CA), and expressed the fusion proteins in DH5 induced with 0.5 mM isopropyl-β-D-thiogalactopyranoside at 30°C for 1 h. We purified the GST-fusion proteins according to the protocol provided by GE Healthcare. We prepared lysates from COS-7 cells (4 x 10⁶) in lysis buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 5 mM MgCl₂, 1% Triton X-100, 1 mM dithiothreitol, 1 mM PMSF, 1 mM sodium orthovanadate, and Complete protease inhibitor tablets) and precleared the lysates with glutathione-Sepharose 4B beads (GE Healthcare). We incubated 10 µg of GST-fusion protein bound to glutathione-Sepharose beads with equal volume of COS-7 cell lysate for 1 h at 4°C. Where indicated, we added the inhibitory peptide SERLI at 50–200 µM. We washed the beads four times, boiled them in 2x SDS sample buffer, and immunoblotted the resulting proteins for ezrin as described above. Immunoblots were stripped and reprobed for GST.

Primary E15 Cortical Neurons
We obtained embryonic day E15 embryos from timed pregnancies of C57BL/6 mice bred in our animal facility. We removed the frontal cortices, minced the tissue, and dissociated the cells by sequential trituration in 0.25% trypsin/0.2% DNAse in S-MEM and then in Neurobasal medium/10% FCS. We plated the cells onto PDL-coated 16-well chamber slides (6 x 10⁴ cells/well) or PDL-coated glass coverslips in 24-well plates (3 x 10⁵ cells/well) in Neurobasal medium supplemented with N2 and B27 (Invitrogen), and we maintained the cultures in 5% CO₂ at 37°C. Where indicated, we transfected the cells with the full-length human Fas coding sequence or the luciferase control vector (0.8 µg of DNA) with 0.5 µl of Lipofectamine 2000 in Opti-MEM. Transfections were performed after 1 d in vitro.

Inhibitors and Antibody Treatments
Six hours after transfection, we changed the media and added agonistic anti-human Fas antibody CH11 (50 ng/ml; Millipore). For untransfected mouse cells, we added agonistic anti-mouse Fas antibody Jo2 (2 µg/ml; BD Biosciences, San Jose, CA) to stimulate endogenous Fas. Inhibitors of mitogen-activated protein kinase kinase (MEK)/ERK (PD98059, 30 µM; Calbiochem, San Diego, CA), of Fas/ezrin interaction (SERLI peptide, 200 µM; GenScript, Piscataway, NJ), or dimethyl sulfoxide vehicle control, were added with the antibodies where indicated. Cells were cultured with the antibodies and/or inhibitors for a further 18 h before fixation. For SH-SY5Y cells analyzed in Figure 8, cells were transfected in six-well plates and then replated onto coverslips 16–20 h after transfection in media already containing SERLI peptide (200 µM) and/or CH11 (50 ng/ml). Fresh inhibitor was added after 6 h, and cells were incubated for a total of 10 h with the inhibitor and/or CH11 before fixation.

Immunofluorescence and Confocal Microscopy
We fixed cells with 4% paraformaldehyde in phosphate-buffered saline (PBS) 18 h after transfection and then permeabilized the cells in 0.25% Triton X-100, blocked them in 10% normal goat serum, and incubated them with anti-FLAG polyclonal antibodies (Sigma-Aldrich) followed by anti-rabbit-Alexa 488 secondary antibodies (Invitrogen), anti-ezrin antibodies (3C12) followed by Cy3-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA), and phalloidin conjugated with Texas Red or Alexa Fluor 647 (Invitrogen) to detect F-actin. We counterstained the nuclei with 4,6-diamidino-2-phenylindole and mounted the slides in Aqua-Poly/Mount (Polysciences, Warrington, PA). Images for analysis of process outgrowth were acquired on a fluorescence microscope (DM IRE2; Leica, Wetzlar, Germany) at 40x magnification by using MetaMorph software (Molecular Devices, Sunnyvale, CA). Images for colocalization were obtained by laser-scanning microscopy (LSM3 PASCAL; Carl Zeiss, Jena, Germany) using LSM 3 PASCAL software version 3.2 for acquisition and image analysis.

Process Outgrowth and Morphometric Analysis
We quantified process growth in transfected cells using phalloidin labeling to define processes on cells staining positive for FLAG, to provide an unbiased comparison between Fas-FLAG and control luc-FLAG-transfected cells. We traced and quantified all actin-positive processes on transfected cells by using MetaMorph software. We defined neurites or primary processes as any processes emerging from the cell body, and branches as any processes emerging from a neurite primary process. For multiple branches, the primary process was defined as the longest continuous path emerging from the cell body. We controlled for general neurotrophic or inhibitory effects of Fas, Fas agonists, and pharmacologic inhibitors by determining cell body area, and we found no significant differences for any treatment.

Statistical Analyses
We compared Fas-transfected and control-transfected or treated and untreated cells using two-tailed unpaired Student's t test for parametric data and Mann–Whitney tests for nonparametric data, and the effect of a series of treatments by one-way analysis of variance. Statistical analyses were performed using Instat GraphPad software (GraphPad Software, San Diego, CA). All figures show mean ± SE.

	RESULTS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Fas Expression Induces Process Outgrowth
We transiently transfected FLAG-tagged full-length human Fas (Fas-FLAG) into a Fas-negative line of SH-SY5Y human neuroblastoma cells. We transfected control cells with luc-FLAG expressed in the same plasmid. We observed a spontaneous change in morphology in cells expressing Fas, but not in the control luciferase-expressing cells, consisting of increased number of processes per cell, and increased frequency of cells extending extremely long processes (Figure 1A). Untransfected and control-transfected SH-SY5Y cells typically produce fine, short spikes spontaneously, and Fas expression significantly increased process density (from 1.5 ± 0.3 to 2.3 ± 0.2 processes/cell). Activation of the Fas receptor with agonistic antibodies to human Fas (clone CH11) triggered a further significant increase in the number of processes per cell in Fas-transfected cells, as well as a striking increase in process branching (Figure 1, B and C). Untransfected SH-SY5Y cells did not express detectable endogenous Fas (as determined by flow cytometry), and they did not respond to agonistic Fas antibody (data not shown).

View larger version (51K): [in this window] [in a new window]   Figure 1. Fas expression induced process growth in neuronal and nonneuronal cell lines. (A) SH-SY5Y cells transfected with control luciferase-FLAG (luc) or full-length human Fas-FLAG (Fas) were labeled with antibodies to FLAG (green) and with phalloidin to detect F-actin (red). Bar, 5 µm. (B) Graphs show average ± SEM length of processes (left), number of processes per cell (middle), and process branching (right), in luc-transfected (white bars), Fas-transfected (pale blue bars), or Fas-transfected cells treated with the Fas agonist CH11 (dark blue bars). (C) Graphs show the effect of blocking ERK activation using PD98059 (PD). Cells were treated as described in B (white, pale blue, or dark blue solid bars), or they were additionally treated with PD98059 (stripped bars). (D) COS-7 cells were transfected and stained as described above. Bar, 5 µm. (E) Fas transfection-induced process growth in COS-7 cells that was not altered significantly by Fas ligation with CH11 or by inhibiting the ERK pathway with PD98059.

We have previously found that the ERK pathway is involved in Fas-mediated neurite growth (Desbarats et al., 2003). We inhibited ERK activation using the pharmacological MEK inhibitor PD98059. Inhibition of the ERK pathway did not change the frequency of COS-7 cells extending processes in response to Fas expression (Figure 1E). However, PD98059 prevented ligand-dependent morphological changes induced by Fas ligation in SH-SY5Y cells (Figure 1C). These data suggested that new processes arising from Fas expression alone, without receptor activation, did not require ERK activation. In contrast, ligand-dependent fine-tuning of process morphology required MEK/ERK function (Figure 1, C and E).

These results showed that Fas could initiate the growth of new processes through an ERK-independent pathway. We next sought to determine the mechanism underlying Fas-induced process growth.

Fas-induced Process Outgrowth Does Not Require the Fas Death Domain
The death domain of Fas is essential for recruitment of FADD and subsequent activation of the proapoptotic caspase cascade (Peter and Krammer, 2003; Zuliani et al., 2006). The death domain consists of six antiparallel -helices. Amino acids 234, 238, 240, and 244, located in helices 2 and 3, are contact residues required for FADD binding (Huang et al., 1996). We produced a truncated FLAG-tagged Fas construct missing helices 2–6 of the death domain. This construct, DD-Fas, consists of residues 1-229 of wild-type human Fas and is lacking all FADD binding residues. We found that DD-Fas was able to induce process growth in COS-7 cells as efficiently as wild-type Fas: 23 ± 1.4% of cells transfected with Fas-FLAG grew processes, compared with 23 ± 0.8% of cells transfected with DD-Fas-FLAG. These results demonstrate that the death domain is not required for Fas to initiate process growth (Figure 2A).

View larger version (34K): [in this window] [in a new window]   Figure 2. Fas-induced process growth does not require the Fas death domain. (A) COS-7 cells transfected with DD-Fas-FLAG extend processes (23 ± 0.8% of COS-7 cells transfected with DD-Fas show process growth, compared with 23 ± 1.4% transfected with full-length Fas-FLAG and 1.6 ± 0.5% with luc-FLAG). Cells were stained with antibodies to FLAG (green) and with phalloidin (red). Bar, 5 µm. (B) COS-7 and mouse HEP1-6 cells were transfected with control luc-FLAG, full-length human Fas-FLAG, or DD-Fas-FLAG, and they were treated with isotype control IgM antibody (white bars) or with CH11 agonistic anti-human Fas antibody (gray bars). COS-7 cells are resistant to Fas-induced apoptosis, whereas full-length Fas, but not DD-Fas, kills apoptosis-sensitive hepatic HEP1-6 cells. Untransfected human Jurkat cells, which express large amounts of endogenous Fas, are included as a Fas-sensitive positive control. Results are expressed as percentage of viable cells compared with untreated cells.

Fas Expression Induces Rac1 Activation
Fas can initiate process growth without using its death domain and without activating ERK. In searching for an alternative molecular mechanism, we reasoned that process growth must involve cytoskeletal rearrangement (Meyer and Feldman, 2002), and it was therefore likely to involve members of the Rho GTPase family, which are essential for process extension and cell motility. These small GTPases consists of the RhoA, Rac1, and Cdc42 families, with RhoA principally responsible for stress fibers formation and cytokinesis, whereas Rac1 and Cdc42 tend to regulate neurite growth (Nikolic, 2002). We asked whether Fas expression in COS-7 cells would activate RhoA, Rac1, or Cdc42 (Figure 3). We used the CRIB domain of human PAK1B as a specific probe for activated Rac1 and Cdc42 in a GST pull-down assay (Manser et al., 1994). This assay specifically detects the activated (GTP-bound forms) of Rac1 and Cdc42. In parallel, we used GST fused to the RBD of ROCK as a probe for activated RhoA. We cotransfected COS-7 cells with luciferase control or Fas, and with myc-tagged Cdc42, Rac1, or RhoA. We found that Fas expression specifically increased the activation of transfected Rac1, but it did not alter the amounts of activated Cdc42 and RhoA in the cell (Figure 3A). To determine whether Fas expression could also activate endogenous Rac1, we transfected COS-7 cells with luciferase control or Fas and then measured endogenous Rac1 activation using GST-CRIB assays. We found that Fas expression induced activation of endogenous Rac1 (Figure 3, B and C). These findings demonstrate a new functional interaction between Fas and Rac1 that may facilitate actin cytoskeletal remodeling.

View larger version (44K): [in this window] [in a new window]   Figure 3. Fas expression induces Rac1 activation. (A) Luciferase or Fas was coexpressed with myc-tagged Rac1, Cdc42, or RhoA in COS-7 cells. GST-CRIB binds activated Rac1 and Cdc42, and GST-RBD binds activated RhoA. Lysate lanes demonstrate total Rac1, Cdc42, or RhoA. (B) COS-7 cells were transfected with luciferase or Fas, and activation of endogenous Rac1 was determined using GST-CRIB pull-down assays. Total endogenous Rac1 was present at undetectable levels in the lysates; therefore, actin was used as a loading control. (C) Densitometry was performed on the immunoblots shown in A and B, and Fas-induced GTPase activation was determined as follows: (activated GTPase/total GTPase) in Fas-transfected cells/(activated GTPase/total GTPase) in Luc-transfected cells. Actin was used as a surrogate for total endogenous Rac1. The graph is representative of five independent experiments showing Fas-induced Rac1 activation.

View larger version (50K): [in this window] [in a new window]   Figure 4. Fas colocalizes and physically interacts with ezrin. (A) Confocal microscopy reveals colocalization of transfected Fas-FLAG (green), endogenous ezrin (red), and F-actin (blue) in COS-7 cells. Fas/ezrin/F-actin triple colocalization is white, and Fas/ezrin colocalization is yellow. Inset shows an enlarged view of the processes. Control cells transfected with luc-FLAG do not show colocalization of FLAG and ezrin. Bar, 5 µm. (B) Lysates from luc-FLAG– or Fas-FLAG–transfected cells were immunoprecipitated (IP) with control IgG, anti-ezrin, or anti-FLAG antibodies, and the IP products were run on duplicate gels. The first gel was immunoblotted (IB) for ezrin (left) and shows that Fas-FLAG, but not luc-FLAG, coprecipitates ezrin. The second gel was immunoblotted with antibodies to FLAG (right), revealing that ezrin coprecipitates Fas-FLAG but not luc-FLAG. HC, heavy chain of IgG.

A Novel Domain of Fas Controls Interaction with ezrin and Is Required for Fas-induced Process Growth
We investigated whether the Fas-ezrin interaction was required for Fas-induced process formation. Ezrin tends to associate with juxtamembrane clusters of basic amino acids (Bretscher, 1999; Tsukita and Yonemura, 1999). The 14 amino acid stretch cytoplasmic to the transmembrane domain of Fas contains a large number of basic residues, KRK (191-193) and RKHRK (200–204), defining a putative ezrin binding region that we have called the Fas MPD. We produced a construct containing a deletion of this region (191-204Fas) (Figure 5A). To determine whether Fas-induced process growth correlated with Fas binding to ezrin, we produced GST fusion proteins of the intracellular domains of full-length Fas (ICD-Fas), ICD-DDFas, and ICD-191-204Fas, and examined their ability to bind ezrin. We found that the intracellular domains of full-length Fas and of DD-Fas associated with ezrin from COS-7 lysates in a GST pull-down assay (Figure 5B). However, the deletion of residues 191-204 abolished the interaction with ezrin (Figure 5B), indicating that Fas 191-204 is essential for association with ezrin. We transfected 191-204Fas-FLAG into COS-7 cells in parallel with Fas-FLAG and DD-Fas-FLAG, and found that 191-204Fas-FLAG was unable to induce process growth (Figure 5, C and D), demonstrating that residues 191-204 of Fas are essential for Fas-induced process growth in these cells. As a control, we also produced a Fas construct lacking the entire intracellular domain (ICD-Fas). This construct was poorly expressed and did not induce process growth (Figure 5C).

View larger version (48K): [in this window] [in a new window]   Figure 5. Fas interacts with ezrin through a 14-amino acid membrane-proximal domain essential for Fas-mediated process growth. (A) The diagram shows the extracellular domain (ECD), transmembrane domain (TM), putative ezrin binding domain (MPD), and DD of full-length Fas, and the GST fusion proteins corresponding to the full-length intracellular domain of Fas (ICDFas), the death-domain deletion (DDFas), and deletion of the MPD (191-204Fas). (B) GST pull-down of ezrin by using the intracellular domains of full-length Fas (ICDFas), DDFas, and 191-204Fas as bait show that ezrin interacts with full-length and DD Fas, but not with 191-204Fas. The blot was stripped and reprobed with anti-GST antibody. (C) Confocal microscopy shows that DDFas, but not 191-204Fas, induces process growth. Fas bearing a deletion of the entire intracellular domain (ICDFas), included as a control, does not induce process growth. Colocalization of FLAG (green) and ezrin (red) is yellow; colocalization of ezrin and actin is pink. Inset shows close-up of processes (merge of Fas and ezrin channels without actin overlay). (D) Full-length and DD Fas induce equivalent process growth in transfected COS-7 cells, but 191-204 Fas fails to induce significant process growth compared with control luc-transfected COS-7 cells. (E) Full-length Fas, but not 191-204Fas, induces significant death in Fas-sensitive HEP 1-6 mouse hepatocytes (p = 0.03; white bars, cells treated with IgM control antibody, gray bars, cells treated with CH11). The amount of cell death in response to CH11 in cells transfected with human Fas is comparable with the maximal cell death induced by the Jo2 anti-mouse Fas antibody (normalized to cells treated with control IgG), which stimulates endogenous Fas on the hepatocytes (black bar).

Our data define a new domain of Fas, the Fas MPD, and they show that the Fas MPD, but not the death domain, is required for Fas-induced process outgrowth.

The Fas MPD Is Required for Fas-induced Rac1 Activation
To examine the mechanistic link between recruitment of ezrin and Rac1 activation, we examined whether the Fas MPD was necessary for Fas-induced Rac1 activation. We transfected COS-7 cells with full-length Fas-FLAG, DD-Fas-FLAG, or 191-204Fas-FLAG. We found that full-length Fas and DD-Fas induced activation of cotransfected myc-tagged Rac1, but that 191-204Fas, which lacks the MPD, did not activate Rac1 (Figure 6, A and B). These data show that Fas-induced Rac1 activation is independent of the death domain, and conversely, that the MPD is required for Fas-induced Rac1 activation.

View larger version (45K): [in this window] [in a new window]   Figure 6. The MPD is required for Fas-induced Rac1 activation. (A) Full-length Fas (wtFas), DDFas, or 191-204Fas was coexpressed with myc-tagged Rac1 in COS-7 cells. Activated Rac1 was pulled down with GST-CRIB and revealed by immunoblotting for myc. Immunoblots of lysates demonstrate total Rac1 expression and actin as a loading control. Results from two independent experiments are shown. (B) Densitometry was performed on the immunoblots shown in A, and Rac1 activation induced by each construct was determined by the ratio of total Rac1 to activated Rac1 for each of the two experiments shown.

View larger version (35K): [in this window] [in a new window]   Figure 7. Exogenous Fas expression and ligation induced neurite growth in primary neurons. (A) Primary cortical neurons from embryonic mice were transfected with luc-FLAG or human Fas-FLAG. Human-Fas–transfected cells were additionally treated with anti-human agonistic Fas antibody (CH11) where shown. CH11 does not cross-react with endogenous mouse Fas expressed on mouse neurons. Images show cortical neurons labeled with antibodies to FLAG (green) and with phalloidin to detect F-actin (red). (B) Neurite growth and branching was quantified for luc-transfected (white bars), Fas-transfected (gray bars), and Fas-transfected/CH11-stimulated neurons (black bars). Neurites were quantified after 2 d in vitro. Graphs show average ± SEM for neurite density expressed as number of neurites per transfected neuron (left), number of branches per transfected neuron (middle), and total summed length of all neurites per transfected neuron (right). p values were calculated using the Mann–Whitney test for nonparametric data.

View larger version (37K): [in this window] [in a new window]   Figure 8. Disruption of the Fas–ezrin interaction prevents Fas-induced process outgrowth. (A) SERLI, a peptide designed to compete with ezrin for binding to Fas, inhibits ezrin binding to Fas in a GST pull-down assay. The graph shows the densitometric ratio of ezrin pulled down by the intracellular domain of Fas (ICDFas) to total ICDFas for peptide concentrations between 0 (no inhibition) and 200 µM (complete inhibition). (B) SERLI inhibits apoptosis in human Jurkat T cells stimulated with CH11. The graph shows decreasing viability of cells treated with CH11 alone (gray triangles), and significant protection from death with addition of SERLI (black circles) or IETD, a peptide inhibitor of caspase-8 (gray squares, dashed line). Averages and standard deviations are shown. (C and D) SH-SY5Y cells were transfected with full-length human Fas-FLAG (white bars) or with control luciferase-FLAG (black bars), cultured overnight, and then replated with CH11 and/or with SERLI, a competitive peptide inhibitor of Fas–ezrin interactions. Processes (C) and branch points (D) per cell were quantified after 10 additional hours in culture with stimulators and/or inhibitors. Graphs show average ± SEM of three replicate cultures. p values show that CH11 induced significant additional process growth and branching in Fas-transfected cells compared with luciferase-transfected cells and that SERLI significantly inhibited processes and branch points in Fas-transfected cells that were not treated with CH11, as well as in Fas-transfected cells treated with CH11. (E and F) Mouse embryonic cortical neurons were treated with antibody to endogenous mouse Fas (Jo2) and/or with SERLI. Neurite density (E) and branching (F) were quantified after 18 h in culture. Stimulation of endogenous Fas induced significant neurite growth and branching, which were prevented by blocking Fas–ezrin interactions with SERLI. Graphs show average ± SEM of four replicate cultures.

	DISCUSSION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Here, we define the upstream molecular interactions underlying Fas-mediated process growth. We describe a new domain of Fas, consisting of 14 membrane-proximal amino acids, that is required for ezrin binding to Fas and subsequent Rac1 activation and process growth. We show that disrupting the association between endogenous Fas and ezrin in cell lines and in primary neurons from embryonic mice prevents Fas-mediated neurite growth. Our findings elucidate a novel Fas-initiated pathway consisting of the Fas MPD, recruitment of ezrin, and Rac1 activation, resulting in process growth. This novel pathway functions independently of the canonical apoptosis cascade consisting of the FADD and caspase activation, resulting in apoptosis.

Ezrin has previously been shown to associate with Fas during apoptosis, resulting in Fas polarization to membrane rafts and uropods, thus promoting efficient apoptosis in activated lymphocytes, CD4⁺ T cells during human immunodeficiency virus infection, and hepatocytes (Luciani et al., 2004; Fais et al., 2005; Haouzi et al., 2005; Charrin and Alcover, 2006). Rac has also been implicated in the death of activated T cells (Ramaswamy et al., 2007). Consistent with this, we found that deletion of the ezrin binding MPD of Fas prevents Fas-induced killing of Fas-sensitive hepatocytes and that blocking the interaction between Fas and ezrin with the SERLI peptide inhibits Fas-dependent apoptosis in Jurkat T cells. However, our findings also reveal that an interaction between Fas and ezrin does not necessarily result in apoptosis but that the outcome of Fas activation is likely context dependent, resulting in apoptosis in activated immune cells and the damaged adult brain, and in neuritogenesis in the developing brain. Ezrin is a member of the ezrin/moesin/radixin (ERM) family of proteins, well characterized molecules that cross-link the cortical actin cytoskeleton with membrane proteins and regulate downstream signaling through a number of mediators, including the Rho GTPases (Bretscher, 1999; Tsukita and Yonemura, 1999). The ERM proteins are essential for the formation of morphological structures such as microvilli, leading edge, and cleavage furrows. Furthermore, ezrin has been implicated in neurite branching and in neurite regeneration after injury, by linking the neural cell adhesion molecule L1 to F-actin in growth cones (Haas et al., 2004; Cheng et al., 2005). Fas and ezrin are both present in neurons in the developing brain, and persists postnatally in neuroproliferative areas (Gimeno et al., 2004).

We have shown that the Fas MPD consists of a stretch of 14 membrane-proximal amino acids. This region, rich in basic amino acids, resembles the ezrin-binding domains of other ezrin-interacting molecules, including L1, β-dystroglycan, CD44, CD43, and intercellular adhesion molecule-2 (Bretscher, 1999; Tsukita and Yonemura, 1999; Cheng et al., 2005). Ezrin has been reported to activate the small GTPases by freeing them from their inhibitor, Rho-GDP dissociation inhibitor (Takahashi et al., 1997). Here, we showed that recruitment of ezrin by Fas allowed Rac1 activation and process growth, suggesting that Fas can remodel cell morphology through posttranscriptional mechanisms, independently of new gene transcription. We and others have reported previously that Fas ligation can activate the ERK pathway (Shinohara et al., 2000; Ahn et al., 2001; O'Brien et al., 2002; Desbarats et al., 2003; Tamm et al., 2004), and Fas-induced ERK activation has been implicated in neurite growth through induction of p35 expression and subsequent activation of the neuron-specific cyclin-dependent kinase 5 (cdk5) (Desbarats et al., 2003). Interestingly, cdk5 phosphorylates ezrin, thereby promoting the association of ezrin with membrane proteins (Yang and Hinds, 2006). Here, we have shown that inhibition of MEK/ERK signaling does not prevent Fas-induced process formation, but rather it reduces the length and branching of processes. Together, these data suggest a model in which Fas binding to ezrin is sufficient to initiate process growth independently of new gene expression, whereas ligation of Fas by FasL can trigger ERK activation, leading to new gene expression that further promotes process elongation and branching via cdk5. Moreover, phosphorylation of ezrin by cdk5 may further promote Fas–ezrin interactions and Fas-mediated process growth.

The physiological function of Fas in the nervous system is being reevaluated in light of recent evidence demonstrating that it is far more than a death receptor (Desbarats et al., 2003; Lambert et al., 2003; Landau et al., 2005; Zuliani et al., 2006; Peter et al., 2007). Fas was initially considered to be exclusively proapoptotic in the nervous system, by analogy with the immune system, where Fas was first described as a "death receptor" (Becher et al., 1998). However, mice with little or no Fas expression (lpr mice) have normal numbers of neurons, despite massively increased numbers of lymphocytes (Watanabe-Fukunaga et al., 1992), suggesting that Fas is not a regulator of physiological neuron death during development (Landau et al., 2005; Zuliani et al., 2006; Peter et al., 2007). In contrast, axon and dendrite branching is reduced in hippocampal and cortical neurons in Fas-deficient lpr mice in vivo, consistent with a role for Fas in promoting neurite branching (Zuliani et al., 2006). Lpr-cg mice, which express Fas that bears a point mutation that inactivates the death domain, also show impaired Fas-mediated neuronal branching (Zuliani et al., 2006), suggesting that the mutation in lpr-cg Fas may affect its binding to ezrin. In vitro, Fas ligation by FasL or agonistic antibodies stimulates neurite growth (Desbarats et al., 2003) and branching (Zuliani et al., 2006) in primary neurons from embryonic and neonatal mice. FasL expression has been reported in neurons, and it may therefore induce autocrine neuritogenesis in neurons in the developing brain. Our data provide insight into the initial molecular steps of Fas-mediated process formation, and they illustrate, for the first time, a new domain of Fas linking Fas to a nonapoptotic pathway.

Fas-induced process growth is likely to have consequences beyond nervous system development. Ezrin-mediated remodeling of cellular morphology has been implicated in tumor motility and metastasis (Curto and McClatchey, 2004; Fais, 2004); interestingly, Fas has also been implicated in tumor progression and invasiveness through activation of NF-B and other nonapoptotic pathways (Barnhart et al., 2004; Peter et al., 2005). Our findings show that Fas–ezrin interactions do not invariably result in cell death, and suggest that this pathway may provide a new mechanism for Fas-mediated cancer progression and metastasis in apoptosis-resistant tumor cells.

Finally, the MPD that we describe here for Fas is homologous with a similar sequence of juxtamembrane basic amino acids found in the Drosophila protein Wengen, the sole Drosophila TNFR superfamily homologue (Kauppila et al., 2003). There is no death domain in Wengen, suggesting that MPD-mediated cytoskeletal remodeling may evolutionarily predate caspase-mediated apoptosis in TNFR superfamily members. Several other members of the TNFR superfamily, including p75 NGFR and TNFR2, also share regions homologous with the Fas MPD. Interestingly, TNFR2 has been preferentially associated with proliferation, whereas TNFR1 has been predominantly implicated in cell death (Aggarwal, 2003).

In summary, we have described a new domain in Fas, shared by several other TNFR superfamily members, that regulates recruitment of ezrin, Rac1 activation, and process growth. The Fas MPD controls a newly defined molecular pathway of morphological differentiation in developing neurons.

	ACKNOWLEDGMENTS

 
We thank R. Siegrist-Johnstone and C. Young for technical assistance; N. Lamarche-Vane for reagents, protocols, and advice on the GTPase activation assays; and E. Cooper, A. Fournier, and J. White for critical comments on the manuscript. This work was supported by Canadian Institutes of Health Research (CIHR) grant 53337 (to J.D.) and a New Investigator operating grant from Parkinson Society Canada (to J.D.) W.R. was supported by postdoctoral fellowships from CIHR and the Parkinson Society Canada, and J.D. was supported by a New Investigator Salary Award from CIHR.

	Footnotes

 
This article was published online ahead of print in MBC in Press (http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E08-02-0161) on May 28, 2008.

* Present address: Tosteson Medical Education Center, Harvard Medical School, Boston, MA 02115.

Address correspondence to: Julie Desbarats (julie.desbarats{at}mcgill.ca)

Abbreviations used: CRIB, Cdc42/Rac1-interactive binding; DD, death domain; ERK, p42/44 extracellular signal-regulated kinase; FADD, Fas-associated death domain; FasL, Fas ligand; ICD, intracellular domain; luc, luciferase; MPD, membrane proximal domain; NGFR, low-affinity p75 nerve growth factor receptor; PAK1B, p21-activated kinase 1 protein 1B; RBD, Rho binding domain; ROCK, Rho-associated kinase; TNFR, tumor necrosis factor receptor.

	REFERENCES

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Aggarwal, B. B. (2003). Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol 3, 745–756.[CrossRef][Medline]

Ahn, J. H., Park, S. M., Cho, H. S., Lee, M. S., Yoon, J. B., Vilcek, J., and Lee, T. H. (2001). Non-apoptotic signaling pathways activated by soluble Fas ligand in serum-starved human fibroblasts. Mitogen-activated protein kinases and NF-kappaB-dependent gene expression. J. Biol. Chem 276, 47100–47106.[Abstract/Free Full Text]

Alderson, M. R., Armitage, R. J., Maraskovsky, E., Tough, T. W., Roux, E., Schooley, K., Ramsdell, F., and Lynch, D. H. (1993). Fas transduces activation signals in normal human T lymphocytes. J. Exp. Med 178, 2231–2235.[Abstract/Free Full Text]

Alderson, M. R., Tough, T. W., Braddy, S., Davis-Smith, T., Roux, E., Schooley, K., Miller, R. E., and Lynch, D. H. (1994). Regulation of apoptosis and T cell activation by Fas-specific mAb. Int. Immunol 6, 1799–1806.[Abstract/Free Full Text]

Barcena, A., Muench, M. O., Song, K. S., Ohkubo, T., and Harrison, M. R. (1999). Role of CD95/Fas and its ligand in the regulation of the growth of human CD34(++)CD38(–) fetal liver cells. Exp. Hematol 27, 1428–1439.[CrossRef][Medline]

Barnhart, B. C., Legembre, P., Pietras, E., Bubici, C., Franzoso, G., and Peter, M. E. (2004). CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 23, 3175–3185.[CrossRef][Medline]

Becher, B., Barker, P. A., Owens, T., and Antel, J. P. (1998). CD95-CD95L: can the brain learn from the immune system? Trends Neurosci 21, 114–117.[CrossRef][Medline]

Bechmann, I., Mor, G., Nilsen, J., Eliza, M., Nitsch, R., and Naftolin, F. (1999). FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier. Glia 27, 62–74.[CrossRef][Medline]

Biancone, L., Martino, A. D., Orlandi, V., Conaldi, P. G., Toniolo, A., and Camussi, G. (1997). Development of inflammatory angiogenesis by local stimulation of Fas in vivo. J. Exp. Med 186, 147–152.[Abstract/Free Full Text]

Bretscher, A. (1999). Regulation of cortical structure by the ezrin-radixin-moesin protein family. Curr. Opin. Cell Biol 11, 109–116.[CrossRef][Medline]

Brunner, T. et al. (1995). Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373, 441–444.[CrossRef][Medline]

Charrin, S., and Alcover, A. (2006). Role of ERM (ezrin-radixin-moesin) proteins in T lymphocyte polarization, immune synapse formation and in T cell receptor-mediated signaling. Front. Biosci 11, 1987–1997.[CrossRef][Medline]

Cheng, L., Itoh, K., and Lemmon, V. (2005). L1-mediated branching is regulated by two ezrin-radixin-moesin (ERM)-binding sites, the RSLE region and a novel juxtamembrane ERM-binding region. J. Neurosci 25, 395–403.[Abstract/Free Full Text]

Choi, C., Gillespie, G. Y., Van Wagoner, N. J., and Benveniste, E. N. (2002). Fas engagement increases expression of interleukin-6 in human glioma cells. J. Neurooncol 56, 13–19.[CrossRef][Medline]

Curto, M., and McClatchey, A. I. (2004). Ezrin. A metastatic detERMinant? Cancer Cell 5, 113–114.[CrossRef][Medline]

Desbarats, J., Birge, R. B., Mimouni-Rongy, M., Weinstein, D. E., Palerme, J. S., and Newell, M. K. (2003). Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat. Cell Biol 5, 118–125.[CrossRef][Medline]

Desbarats, J., and Newell, M. K. (2000). Fas engagement accelerates liver regeneration after partial hepatectomy. Nat. Med 6, 920–923.[CrossRef][Medline]

Desbarats, J., Wade, T., Wade, W. F., and Newell, M. K. (1999). Dichotomy between naïve and memory CD4⁺ T cell responses to Fas (CD95) engagement. Proc. Natl. Acad. Sci. USA 96, 8104–8109.[Abstract/Free Full Text]

Dhein, J., Walczak, H., Baumler, C., Debatin, K.-M., and Krammer, P. H. (1995). Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373, 438–441.[CrossRef][Medline]

Fais, S. (2004). A role for ezrin in a neglected metastatic tumor function. Trends Mol. Med 10, 249–250.[CrossRef][Medline]

Fais, S., De Milito, A., and Lozupone, F. (2005). The role of FAS to ezrin association in FAS-mediated apoptosis. Apoptosis 10, 941–947.[CrossRef][Medline]

French, L. E., and Tschopp, J. (1996). Constitutive Fas ligand expression in several non-lymphoid mouse tissues: implications for immune protection and cell turnover. Behring Inst. Mitteilungen 97, 156–160.[Medline]

Gimeno, L., Corradi, A., Cobos, I., Consalez, G. G., and Martinez, S. (2004). Ezrin gene, coding for a membrane-cytoskeleton linker protein, is regionally expressed in the developing mouse neuroepithelium. Gene Expr. Patterns 4, 749–754.[CrossRef][Medline]

Haas, M. A., Vickers, J. C., and Dickson, T. C. (2004). Binding partners L1 cell adhesion molecule and the ezrin-radixin-moesin (ERM) proteins are involved in development and the regenerative response to injury of hippocampal and cortical neurons. Eur. J. Neurosci 20, 1436–1444.[CrossRef][Medline]

Haouzi, D., Baghdiguian, S., Granier, G., Travo, P., Mangeat, P., and Hibner, U. (2005). Three-dimensional polarization sensitizes hepatocytes to Fas/CD95 apoptotic signalling. J. Cell Sci 118, 2763–2773.[Abstract/Free Full Text]

Huang, B., Eberstadt, M., Olejniczak, E. T., Meadows, R. P., and Fesik, S. W. (1996). NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature 384, 638–641.[CrossRef][Medline]

Ivetic, A., and Ridley, A. J. (2004). Ezrin/radixin/moesin proteins and Rho GTPase signalling in leucocytes. Immunology 112, 165–176.[CrossRef][Medline]

Ju, S. T., Panka, D. J., Cui, H., Ettinger, R., El-Khatib, M., Sherr, D. H., Stanger, B. Z., and Marshak-Rothstein, A. (1995). Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373, 444–448.[CrossRef][Medline]

Kauppila, S. et al. (2003). Eiger and its receptor, Wengen, comprise a TNF-like system in Drosophila. Oncogene 22, 4860–4867.[CrossRef][Medline]

Lambert, C., Landau, A. M., and Desbarats, J. (2003). Fas–beyond death: a regenerative role for Fas in the nervous system. Apoptosis 8, 551–562.[CrossRef][Medline]

Landau, A. M., Luk, K. C., Jones, M. L., Siegrist-Johnstone, R., Young, Y. K., Kouassi, E., Rymar, V. V., Dagher, A., Sadikot, A. F., and Desbarats, J. (2005). Defective Fas expression exacerbates neurotoxicity in a model of Parkinson's disease. J. Exp. Med 202, 575–581.[Abstract/Free Full Text]

Lozupone, F., Lugini, L., Matarrese, P., Luciani, F., Federici, C., Iessi, E., Margutti, P., Stassi, G., Malorni, W., and Fais, S. (2004). Identification and relevance of the CD95-binding domain in the N-terminal region of ezrin. J. Biol. Chem 279, 9199–9207.[Abstract/Free Full Text]

Luciani, F., Matarrese, P., Giammarioli, A. M., Lugini, L., Lozupone, F., Federici, C., Iessi, E., Malorni, W., and Fais, S. (2004). CD95/phosphorylated ezrin association underlies HIV-1 GP120/IL-2-induced susceptibility to CD95(APO-1/Fas)-mediated apoptosis of human resting CD4(+)T lymphocytes. Cell Death Differ 11, 574–582.[CrossRef][Medline]

Manser, E., Leung, T., Salihuddin, H., Zhao, Z. S., and Lim, L. (1994). A brain serine/threonine protein kinase activated by Cdc42 and Rac1. Nature 367, 40–46.[CrossRef][Medline]

Martin-Villalba, A., Hahne, M., Kleber, S., Vogel, J., Falk, W., Schenkel, J., and Krammer, P. H. (2001). Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ 8, 679–686.[CrossRef][Medline]

Meyer, G., and Feldman, E. L. (2002). Signaling mechanisms that regulate actin-based motility processes in the nervous system. J. Neurochem 83, 490–503.[CrossRef][Medline]

Nagata, S., and Golstein, P. (1995). The Fas death factor. Science 267, 1449–1456.[Abstract/Free Full Text]

Nikolic, M. (2002). The role of Rho GTPases and associated kinases in regulating neurite outgrowth. Int. J. Biochem. Cell Biol 34, 731–745.[CrossRef][Medline]

O'Brien, D., O'Connor, T., Shanahan, F., and O'Connell, J. (2002). Activation of the p38 MAPK and ERK1/2 pathways is required for Fas-induced IL-8 production in colonic epithelial cells. Ann. N Y Acad. Sci 973, 161–165.[Medline]

Parlato, S., Giammarioli, A. M., Logozzi, M., Lozupone, F., Matarrese, P., Luciani, F., Falchi, M., Malorni, W., and Fais, S. (2000). CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway. EMBO J 19, 5123–5134.[CrossRef][Medline]

Peter, M. E. et al. (2007). The CD95 receptor: apoptosis revisited. Cell 129, 447–450.[CrossRef][Medline]

Peter, M. E., and Krammer, P. H. (2003). The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 10, 26–35.[CrossRef][Medline]

Peter, M. E., Legembre, P., and Barnhart, B. C. (2005). Does CD95 have tumor promoting activities? Biochim. Biophys. Acta 1755, 25–36.[Medline]

Ramaswamy, M., Dumont, C., Cruz, A. C., Muppidi, J. R., Gomez, T. S., Billadeau, D. D., Tybulewicz, V.L.J., and Siegel, R. M. (2007). Rac GTPases sensitize activated T cells to die via Fas. J. Immunol 179, 6384–6388.[Abstract/Free Full Text]

Raoul, C., Estevez, A. G., Nishimune, H., Cleveland, D. W., deLapeyriere, O., Henderson, C. E., Haase, G., and Pettmann, B. (2002). Motoneuron death triggered by a specific pathway downstream of Fas. Potentiation by ALS-linked SOD1 mutations. Neuron 35, 1067–1083.[CrossRef][Medline]

Ricci-Vitiani, L., Pedini, F., Mollinari, C., Condorelli, G., Bonci, D., Bez, A., Colombo, A., Parati, E., Peschle, C., and De Maria, R. (2004). Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death. J. Exp. Med 200, 1257–1266.[Abstract/Free Full Text]

Sakic, B., Szechtman, H., Denburg, J., Gorny, G., Kolb, B., and Whishaw, I. (1998). Progressive atrophy of pyramidal neuron dendrites in autoimmune MRL-lpr mice. J. Neuroimmunol 87, 162–170.[CrossRef][Medline]

Shinohara, H., Yagita, H., Ikawa, Y., and Oyaizu, N. (2000). Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase. Cancer Res 60, 1766–1772.[Abstract/Free Full Text]

Takahashi, K., Sasaki, T., Mammoto, A., Takaishi, K., Kameyama, T., Tsukita, S., and Takai, Y. (1997). Direct interaction of the Rho GDP dissociation inhibitor with ezrin/radixin/moesin initiates the activation of the Rho small G protein. J. Biol. Chem 272, 23371–23375.[Abstract/Free Full Text]

Tamm, C., Robertson, J. D., Sleeper, E., Enoksson, M., Emgard, M., Orrenius, S., and Ceccatelli, S. (2004). Differential regulation of the mitochondrial and death receptor pathways in neural stem cells. Eur. J. Neurosci 19, 2613–2621.[CrossRef][Medline]

Trauth, B. C., Klas, C., Peters, A. M., Matzku, S., Moller, P., Falk, W., Debatin, K. M., and Krammer, P. H. (1989). Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245, 301–305.[Abstract/Free Full Text]

Tsukita, S., and Yonemura, S. (1999). Cortical actin organization: lessons from ERM (ezrin/radixin/moesin) proteins. J. Biol. Chem 274, 34507–34510.[Free Full Text]

Tsutsui, H. et al. (1999). Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity 11, 359–367.[CrossRef][Medline]

Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., and Nagata, S. (1992). Lymphoproliferative disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356, 314–317.[CrossRef][Medline]

Yang, H. S., and Hinds, P. W. (2006). Phosphorylation of ezrin by cyclin-dependent kinase 5 induces the release of Rho GDP dissociation inhibitor to inhibit Rac1 activity in senescent cells. Cancer Res 66, 2708–2715.[Abstract/Free Full Text]

Yonehara, S., Ishii, A., and Yonehara, M. (1989). A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med 169, 1747–1756.[Abstract/Free Full Text]

Zuliani, C. et al. (2006). Control of neuronal branching by the death receptor CD95 (Fas/Apo-1). Cell Death Differ 13, 31–40.[CrossRef][Medline]

This Article Abstract Full Text (PDF) All Versions of this Article: E08-02-0161v1 19/8/3192    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ruan, W. Articles by Desbarats, J. Search for Related Content PubMed PubMed Citation Articles by Ruan, W. Articles by Desbarats, J.